Poster session 2, Abstracts 345–694

Identifieur interne : 000A86 ( Main/Exploration ); précédent : 000A85; suivant : 000A87

---

Poster session 2, Abstracts 345–694

Auteurs :

Source :

• Movement Disorders [ 0885-3185 ] ; 2004.

RBID : ISTEX:9983535EB14CA07ACB4DE93558D159E27231B32D

English descriptors

• Teeft :
  • Abnormality, Acupuncture, Adjunctive, Adverse effects, Adverse events, Agonist, Akinesia, Allele, Amantadine, Ameliorate, Animal models, Anova, Antidepressant, Antiparkinsonian, Antiparkinsonian drugs, Antipsychotic, Apomorphine, Asymmetry, Asymptomatic, Atypical, Auditory, Autonomic dysfunction, Autonomic function, Autosomal, Aviv, Axial symptoms, Barbosa, Barcelona, Basal, Basal ganglia, Baseline, Beck depression inventory, Beta, Bilateral, Bilaterally, Bipolar, Bladder, Bladder dysfunction, Bladder symptoms, Blepharospasm, Blood pressure, Blood samples, Bradykinesia, Brain stimulation, Bromocriptine, Cabergoline, Cabergoline therapy, Cannabis, Carbidopa, Cardiac, Cardiac uptake, Cardiovascular, Caregiver, Caregiver burden, Caudate, Cell death, Clinic, Clinical characteristics, Clinical diagnosis, Clinical features, Clinician, Cognition, Cognitive, Cognitive decline, Cognitive function, Cognitive functions, Cognitive impairment, Cohort, Complication, Compulsive behavior, Computerized, Comt, Comt inhibitor, Comt inhibitors, Concomitant, Consecutive patients, Contralateral, Control group, Control subjects, Correlated, Cue, Cueing, Cytoplasmic, Daily dose, Dalys, Database, Deep brain stimulation, Degeneration, Deletion, Demented, Demented patients, Dementia, Depressive, Depressive symptoms, Diagnostic criteria, Diastolic, Discontinuation, Disease, Disease duration, Disease duration years, Disease onset, Disease patients, Disease progression, Disease rating scale, Disease severity, Disord, Disorder, Dlas, Dopamine, Dopamine agonist, Dopamine agonist therapy, Dopamine agonists, Dopamine neurons, Dopamine receptors, Dopaminergic, Dopaminergic agents, Dopaminergic drugs, Dopaminergic medication, Dopaminergic neurons, Dopaminergic therapy, Dopaminergic treatment, Dorsal, Dorsolateral, Dos, Dose, Dosing, Double vision, Duodopa, Duration, Dysfunction, Dyskinesia, Dystonia, Early disease, Early stage, Early stages, Edema, Electrophysiological, Elegans, Endpoint, Entacapone, Eopd, Epworth, Etiology, Executive function, Executive functions, Exercise program, Exion, Exon, Extracellular, Family history, Fdopa, Fdopa uptake, Festination, Folate, Forebrain, Fpeak, Frsbe, Further studies, Gait, Gait analysis, Gait cycle, Gait speed, Gait stability, Gait variability, Ganglion, Gender, Gender differences, Genomic, Genotype, Giladi, Glia, Glial, Glial cells, Hallucination, Hand deformity, Handedness, Haplotype, Hausdorff, Healthy controls, Healthy subjects, Heart rate, Hemiparkinsonian, Hippocampus, Hoehn, Homocysteine, Homocysteine levels, Hong kong, Hybridization, Hydroxylase, Hyperhomocysteinemia, Hypotension, Idiopathic, Idiopathic disease, Immunohistochemical, Immunohistochemistry, Immunoreactivity, Impairment, Important role, Impulse control, Inclusion criteria, Incontinence, Infusion, Inhibitor, Intelligibility, Intermittent subcutaneous, Intermittent subcutaneous apomorphine, International congress, Intraduodenal, Intraoperative, Intravenous, Ipsilateral, Iron levels, Isometric, January, June, Kinase, Kinematic, Lactacystin, Largo, Latency, Lesion, Lesioned, Levetiracetam, Levodopa, Levodopa dose, Levodopa medication, Levodopa therapy, Levodopa treatment, Lewy, Lewy bodies, Locomotor, Locomotor activity, Macaque, Major role, Many patients, Maobi, Marmoset, Marti, Mdrs, Med, Medial, Median, Medication, Mental loading, Mibg, Microglial, Midbrain, Milnacipran, Mini, Mirtazapine, Mirtazapine group, Mizuno, Mmse, Monoamine, Monotherapy, Motor complications, Motor control, Motor cortex, Motor function, Motor impairment, Motor improvement, Motor performance, Motor score, Motor symptoms, Movement disorders, Mptp, Mrna, Msec, Multivariate, Mutation, Navajo, Nding, Ndings, Neurodegeneration, Neurodegenerative, Neurol, Neuroleptic, Neurological, Neurologist, Neurology, Neuron, Neuron density, Neuronal, Neuropathological, Neuroprotection, Neuroprotective, Neuropsychological, Neuropsychological tests, Nger, Nicotine, Nigra, Nigral, Nigrostriatal, Nmda, Normal controls, Normal subjects, Normal values, Nurr1, Nurse practitioners, Nyholm, Odds ratio, Olfactory, Ongoing, Optimized, Oral festination, Orthostatic, Orthostatic hypotension, Orthostatic intolerance, Oscillatory, Outcome measures, Outpatient, Overexpression, Oxidative, Oxidative stress, Pallidal, Pallidotomy, Panic attacks, Parietal, Park2, Parkin, Parkin gene, Parkin gene mutations, Parkinson, Parkinson disease, Parkinson patients, Parkinsonian, Parkinsonian patients, Parkinsonian symptoms, Parkinsonism, Parkinsons disease, Pathogenesis, Pathophysiology, Pathway, Patient, Paulo, Pd_fog, Pdql, Pergolide, Peripheral edema, Pesticide, Pharmacokinetic, Phenotype, Physical therapy, Pilot study, Piribedil, Placebo, Placebo group, Plantar, Plasma levels, Platelet, Polymorphism, Poster, Poster session, Postural, Postural control, Postural instability, Postural stability, Pramipexole, Preclinical, Predictor, Prefrontal, Prefrontal cortex, Preliminary results, Present study, Prevalence, Previous studies, Previous study, Progenitor, Prospective study, Proteasomal, Proteasome, Proteasome activity, Psychosis, Psychotic, Psychotic symptoms, Putamen, Pyridoxine, Quadrant, Raav, Randomised, Randomised trials, Randomized, Rasagiline, Rating scale, Rcbf, Receptor, Recessive, Release test, Responder, Rhythmic cues, Rhythmicity, Rigidity, Rimantadine, Risk factor, Risk factors, Ropinirole, Rotigotine, Rtms, Saccade, Safety errors, Sedation, Selegiline, Sensorimotor, Sequence effect, Sequencing, Serotonin, Sert, Severity, Sham, Sibling, Side effects, Simulator, Sirna, Sleepiness, Snca, Somnolence, Spect, Speech rate, Speech therapy, Spontaneous speech, Stalevo, State examination, Statin, Statistical analysis, Step initiation, Stimulation, Stimulator, Striatal, Striatum, Stride length, Stride variability, Stroop, Subcutaneous, Subcutaneous apomorphine, Subgroup, Subset, Substantia, Substantia nigra, Subthalamic, Subthalamic nucleus, Subthalamotomy, Subunit, Suppl, Sural, Surgical, Swing time, Swing time variability, Symptom, Symptomatology, Symptoms onset, Syndrome, Synuclein, Synuclein expression, Synuclein gene, Systematic review, Systolic, Thalamus, Thcy, Therapy, Tolcapone, Tolerability, Tolosa, Tomography, Total score, Toxicity, Transcranial, Transfected, Transgenic, Transporter, Treadmill, Treatment period, Tremor, Trimethobenzamide, Tyrosine hydroxylase, Ubiquitin, Uctuations, Uency, Ultrasound, Updrs, Updrs motor score, Updrs motor scores, Updrs part, Updrs score, Updrs scores, Updrs3, Updrsm, Urinary symptoms, Variability, Vascular parkinsonism, Visual cueing, Visual guidance, Visual information, Welder, Wilcoxon, Yahr, Yahr scale, Yahr stage.

Url:

• https://api.istex.fr/document/9983535EB14CA07ACB4DE93558D159E27231B32D/fulltext/pdf

DOI: 10.1002/mds.20176

Affiliations:

---

Links toward previous steps (curation, corpus...)

• to stream Istex, to step Corpus: 000F94
• to stream Istex, to step Curation: 000F16
• to stream Istex, to step Checkpoint: 000881
• to stream Main, to step Merge: 000A86
• to stream Main, to step Curation: 000A86

---

Le document en format XML

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sarre/explor/MusicSarreV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A86 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A86 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sarre
   |area=    MusicSarreV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:9983535EB14CA07ACB4DE93558D159E27231B32D
   |texte=   Poster session 2, Abstracts 345–694
}}

---

This area was generated with Dilib version V0.6.33. Data generation: Sun Jul 15 18:16:09 2018. Site generation: Tue Mar 5 19:21:25 2024